Omics for Biomarker Investigation in Neurodegenerative Diseases
- Authors: Aiman Tanveer1, Dinesh Yadav2
-
View Affiliations Hide Affiliations1 Department of Biotechnology, DDU Gorakhpur University, Gorakhpur, India 2 Department of Biotechnology, DDU Gorakhpur University, Gorakhpur, India
- Source: Neurodegenerative Diseases: Multifactorial Degenerative Processes, Biomarkers and Therapeutic Approaches , pp 143-160
- Publication Date: August 2022
- Language: English
Omics for Biomarker Investigation in Neurodegenerative Diseases, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9789815040913/chap10-1.gif
Neurodegenerative disease such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, frontotemporal dementia, and the spinocerebellar ataxias is major health threat specifically in the elderly population. Currently, the disease diagnosis and progression is tracked through the clinical estimation which only gives a rough estimate of the disease severity. So the biomarkers serve as an essential tool in the disease diagnosis and disease progression. High-throughput omics-based technologies have facilitated the discovery of new biomarkers. The analytic methods underlying the basic omics-based technologies, genomics, transcriptomics, and metabolomics are now been extensively useful in the identification of novel biomarkers. These new candidate biomarkers are helpful in the clinical management of neurological disorders.
-
From This Site
/content/books/9789815040913.chap10dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
